- Nektar Therapeutics Inc NKTR has entered into a new oncology clinical collaboration with Merck KGaA MKGAF and Pfizer Inc PFE to evaluate the maintenance regimen of NKTR-255 in combination with avelumab in bladder cancer study.
- The Phase 2 JAVELIN Bladder Medley study will include locally advanced or metastatic urothelial carcinoma (UC) patients.
- NKTR-255 is wholly owned by Nektar and is currently being evaluated in two separate clinical studies in both liquid and solid tumors.
- Avelumab is marketed in the U.S. as Bavencio, is co-developed and co-commercialized by Merck KGaA and Pfizer.
- The study will begin enrolling patients in Q1 of 2022.
- Price Action: NKTR shares are up 4.53% at $17.08 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsMoversTrading IdeasGeneralbladder cancerBriefsPhase 2 Clinical Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
